HomeCompareHYRE vs ABBV

HYRE vs ABBV: Dividend Comparison 2026

HYRE yields 10810.81% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HYRE wins by $118928106307211072.00M in total portfolio value
10 years
HYRE
HYRE
● Live price
10810.81%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$118928106307211072.00M
Annual income
$116,802,746,013,914,210,000,000.00
Full HYRE calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HYRE vs ABBV

📍 HYRE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHYREABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HYRE + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HYRE pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HYRE
Annual income on $10K today (after 15% tax)
$918,918.92/yr
After 10yr DRIP, annual income (after tax)
$99,282,334,111,827,070,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, HYRE beats the other by $99,282,334,111,827,070,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HYRE + ABBV for your $10,000?

HYRE: 50%ABBV: 50%
100% ABBV50/50100% HYRE
Portfolio after 10yr
$59464053153605536.00M
Annual income
$58,401,373,006,957,110,000,000.00/yr
Blended yield
98.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HYRE
Analyst Ratings
4
Buy
Consensus: Buy
Altman Z
-8.0
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HYRE buys
0
ABBV buys
0
No recent congressional trades found for HYRE or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHYREABBV
Forward yield10810.81%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$118928106307211072.00M$102.3K
Annual income after 10y$116,802,746,013,914,210,000,000.00$24,771.77
Total dividends collected$118786858956819104.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: HYRE vs ABBV ($10,000, DRIP)

YearHYRE PortfolioHYRE Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,091,781$1,081,081.08$11,550$430.00+$1.08MHYRE
2$111,476,979$110,308,773.03$13,472$627.96+$111.46MHYRE
3$10,645,584,214$10,526,303,847.00$15,906$926.08+$10645.57MHYRE
4$950,846,752,666$939,455,977,556.29$19,071$1,382.55+$950846.73MHYRE
5$79,438,642,241,516$78,421,236,216,164.00$23,302$2,095.81+$79438642.22MHYRE
6$6,208,097,080,727,997$6,123,097,733,529,574.00$29,150$3,237.93+$6208097080.70MHYRE
7$453,855,335,707,848,450$447,212,671,831,469,440.00$37,536$5,121.41+$453855335707.81MHYRE
8$31,041,116,362,181,130,000$30,555,491,152,973,730,000.00$50,079$8,338.38+$31041116362181.08MHYRE
9$1,986,318,031,118,582,200,000$1,953,104,036,611,048,300,000.00$69,753$14,065.80+$1986318031118582.25MHYRE
10$118,928,106,307,211,070,000,000$116,802,746,013,914,210,000,000.00$102,337$24,771.77+$118928106307211072.00MHYRE

HYRE vs ABBV: Complete Analysis 2026

HYREStock

HyreCar Inc., together with subsidiaries, operates a web-based car-sharing marketplace in the United States. Its marketplace allows car and fleet owners to rent their idle cars to ride-sharing service drivers, such as Uber and Lyft drivers. HyreCar Inc. was incorporated in 2014 and is headquartered in Los Angeles, California.

Full HYRE Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HYRE vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HYRE vs SCHDHYRE vs JEPIHYRE vs OHYRE vs KOHYRE vs MAINHYRE vs JNJHYRE vs MRKHYRE vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.